Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN6490 Safety and PK in Healthy Volunteers
NCT04616079Phase 1Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2020
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN6490 in palmoplantar pustulosis (PPP) (8 cohorts), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Incidence and severity of Treatment-Emergent Adverse Events (TEAEs). Started Nov 2020; status: terminated.
02
Drugs
REGN6490
03
Conditions
palmoplantar pustulosis (PPP)
Beyond the preview
Go deeper on NCT04616079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04616079.